TABLE 1.
Clinically Approved Nanoparticles
| Type | Size (nm) | Agent | Modality | Indication | Trade name |
| Sulfur colloid | 100–300 | 99mTc | SPECT | Lymphoscintigraphy, bone marrow, gastrointestinal, liver and spleen | Technecoll (US) |
| Albumin colloid | 6–80 | 99mTc | SPECT | Lymphoscintigraphy, inflammation imaging, melanoma, prostate | Nanocoll (EU) |
| SnF2 colloid | <200 | 99mTc | SPECT | Lymphoscintigraphy, gastrointestinal, liver and spleen | Hepatate (France) |
| Re2S7 colloid | 10–70 | 99mTc | SPECT | Lymphoscintigraphy, gastrointestinal, melanoma, prostate | Nanocis (EU) |
| Albumin colloid | 100–600 | 99mTc | SPECT | Lymphoscintigraphy of breast | Senti-Scint |
| Dextran-coated iron oxide (ferumoxide) | 80–150 | Fe2+ Fe3+2O4 (Fe3+ Fe2+2)O4 | MRI | Mononuclear phagocyte system imaging, cellular labeling. | Feridex (US), Endorem (Britain) |
| Dextran-coated iron oxide (ferumoxtran) | 20–40 | Fe2+ Fe3+2O4 (Fe3+ Fe2+2)O4 | MRI | Lymph node imaging, perfusion imaging | Sinerem (EU), Combidex (US) |
| Carboxydextran-coated iron oxide (ferucarbotran) | 60 | γ-Fe2O3 | MRI | Hepatocellular carcinoma, cell labeling | Resovist (US, EU), Cliavist (France) |
| Polyglucose sorbitol carboxymethylether-coated iron oxide (ferumoxytol) | 17–30 | γ-Fe2O3 | MRI | Iron-deficiency anemia, off-label uses in imaging | Faraheme (US) |